MedTrace Logo

Parkinson's Disease Inflammatory Biomarker Profiling

NCT03633513 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 99

Last updated 2024-04-18

No results posted yet for this study

Summary

This study compares a comprehensive panel of immunological biomarkers between Parkinson's disease patients and healthy, environmentally matched participants. This unique study design provides the ability to control for differences in environment between study subjects. The goal of this study is to 1) identify a specific set of immunological markers that correlate with a clinical diagnosis of Parkinson's disease and 2) stratify patients by disease severity using these same biomarkers.

Conditions

  • Parkinson Disease

Interventions

DIAGNOSTIC_TEST

LBT-3627

Immunomodulatory agent

DIAGNOSTIC_TEST

Immunological profiling

Comprehensive profiling of inflammatory and anti-inflammatory markers (incl. cellular, molecular) including cellular functional assays

Sponsors & Collaborators

  • Michael J. Fox Foundation for Parkinson's Research

    collaborator OTHER

  • Corporal Michael J. Crescenz VA Medical Center - Philadelphia

    collaborator UNKNOWN

  • Longevity Biotech

    lead INDUSTRY

Principal Investigators

  • Scott Shandler, PhD · Longevity Biotech, Inc

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-10
Primary Completion
2020-03-13
Completion
2020-03-13

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03633513 on ClinicalTrials.gov